Research Paper

Prognostic Values of TIGAR Expression and $^{18}$F-FDG PET/CT in Clear Cell Renal Cell Carcinoma

Xiaoyan Wang2*, Rui Li1*, Ruohua Chen1, Gang Huang1,3, Xiang Zhou1, Jianjun Liu1

1. Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2. Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
3. Shanghai Key Laboratory for Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China

*These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2019.01.23; Accepted: 2019.08.18; Published: 2020.01.01

Abstract

Aim: Evaluation of $^{18}$F-FDG accumulation using PET/CT is an potential imaging biomarker to reflect tumor metabolic burdens and to help predict prognosis in renal cell carcinoma (RCC). p53-induced glycolysis and apoptosis regulator (TIGAR) is a protein regulates glycolytic activity and glucose metabolism. The deregulated TIGAR expression has been associated with tumorigenesis and poor disease prognosis in several cancers. The purpose of this study is to evaluate the impact of the TIGAR expression and the maximum standardized uptake value (SUVmax) of $^{18}$F-FDG PET/CT on survival for patients with clear cell RCC.

Methods: A total of 62 patients with confirmed clear cell RCC were included in this retrospective study. The TIGAR expression of tumors were determined through immunohistochemistry staining. The SUVmax of clear cell RCC lesions were assessed using $^{18}$F-FDG PET/CT. The impact of TIGAR expression and SUVmax on overall survival was evaluated by the Cox proportional hazards model and the Kaplan-Meier survival analysis.

Results: Increased TIGAR staining was associated in clear cell RCC patients with older age, venous tumor thrombus, or increased SUVmax. A positive correlation was found between TIGAR expression and SUVmax in patients ($r=0.396$, $P=0.001$). Patients with positive TIGAR expression had a decreased overall survival time than those with negative TIGAR expression. The overall survival time was significantly shorter in patients with high SUVmax (>5.25) compared with those with low SUVmax ($\leq 5.25$). SUVmax and Fuhrman grade were identified as independent prognostic factors in clear cell RCC. Patients with high SUVmax (>5.25) and positive TIGAR expression were associated with a worse disease prognosis.

Conclusion: The expression of TIGAR is significantly correlated with SUVmax in clear cell RCC. The combined use of TIGAR expression and $^{18}$F-FDG PET/CT can provide additional information for tumor glucose metabolic status and disease prognosis in patients with clear cell RCC.

Key words: Renal cell carcinoma, PET/CT, TIGAR, SUVmax

Introduction

In adults, renal cell carcinoma (RCC) is the most common type of kidney cancer and accounts for about 90–95% of cancerous cases arising from the kidney [1, 2]. Over the past decades, the incidence of RCC increases at a rate around 2% annually, partly due to the improved detecting ability of imaging modalities [3]. Most cases are asymptomatic in clinic, often present with non-specific symptoms including weight loss and fever. Less than 15% of RCC cases present with the classic triad (hematuria, flank pain and flank
mass) at the time of diagnosis and are associated with advanced disease [4]. About 30% of RCC patients were reported with metastatic spread by the time of diagnosis [5]. Clear cell RCC is the most common histologic type in RCC, responsible for approximately 70%-80% of RCC cases [6]. Patients with clear cell RCC has been shown to have an equivalent or worse prognosis compared with other histologic types, with 5 year survival rate around 50-75% [6-8]. According to previous multivariate analysis, certain factors including tumor size, Fuhrman grade, nuclear grade and components of tumor stage (T, N and M stage) were associated with disease survival in patients with clear cell RCC [7, 9-11].

\[ \text{SUV}_{\text{max}} \] is a robust metric for the assessment of FDG uptake and glucose metabolic activity of tumors in vivo [15]. Previous studies have suggested a \[ \text{SUV}_{\text{max}}>8.8 \] is associated with poor prognosis in 26 patients with advanced RCC [16]. Another 12 month follow-ups study also revealed an association between high disease mortality with high \[ \text{SUV}_{\text{max}}>10 \] in 60 patients with RCC [17]. Bases on these preliminary data, it is likely that \[ \text{SUV}_{\text{max}} \] may provide quantitative measurement of glucose metabolism of tumor lesion and predict disease prognosis in patients with RCC.

Recently, assessment of changes in molecular pathways has been shown to provide additional survival information in RCC patients. p53-induced glycolysis and apoptosis regulator (TIGAR) is a protein regulated in the p53 tumor suppressor pathways and serves an important regulatory role in the glucose metabolism of tumors [18, 19]. Previous studies have suggested an association between the status of TIGAR expression and disease prognosis in patients with chronic lymphocytic leukemia, acute myeloid leukemia and non-small cell lung cancer [20-22]. Moreover, p53 immunoreactivity has been recognized as a prognostic factor for RCC. Patients with p53-positive clear cell RCC was shown to have a significantly lower survival rate than those with p53-negative tumors [23]. It is believed that TIGAR is activated by p53 and in turn inhibits the glycolytic activity and promote pentose phosphate pathway (PPP) [24]. However, to our knowledge, there is no clinical study evaluated the value of TIGAR expression in predicting disease survival in patients with RCC.

Hence, the purpose of this retrospective study is to examine the correlation between TIGAR expression and \(^{18}\)F-FDG PET/CT imaging parameters in patients with clear cell RCC. In addition, we further determine whether TIGAR expression and \[ \text{SUV}_{\text{max}} \] could serve as predictive factors for disease survival in these patients.

**Methods**

**Study population**

62 patients with known RCC were recruited in this retrospective study in Shanghai Jiao Tong University affiliated Renji Hospital from April 2010 to June 2016. All patients received \(^{18}\)F-FDG PET/CT examination before the surgery and were confirmed to have clear cell RCC based on their histological findings. Patients were eligible for the study if (1) they did not received chemotherapy or radiotherapy before the \(^{18}\)F-FDG PET/CT examination; (2) the interval between \(^{18}\)F-FDG PET/CT scan and surgery was no more than 2 weeks; (3) complete medical records including patient demographics, clinical data and follow-up information were available; (4) surgical specimens of tumor lesions were available for immunohistochemical analysis. This study is approved by the Human Investigation Ethical Committee of Shanghai Jiao Tong University affiliated Renji Hospital. All patients signed the informed consent. All steps are in conformity with the Helsinki declaration.

**PET/CT imaging**

All patients received a whole-body \(^{18}\)F-FDG PET/CT scan with a Biograph 64 PET/CT system (Siemens Medical Systems, German). Patients were fasted for 4-6 hours to reach a blood sugar level lower than 6.3mmol/L. Intravenous injection of 5.55MBq/kg \(^{18}\)F-FDG (radiochemical purity > 95%; provided by Shanghai Kexin Pharmaceutical Co. Ltd.) was administrated according to the body weight of patient 60min before the imaging. All patient took the supine position, and the area from the base of the skull to the middle of the femur was scanned during CT and PET imaging. CT scan was performed using voltage 120kv and current 140mA. Following parameters were applied in the PET scan: 3D model, 2min/ beds, matrix 128*128. After the image acquisition was completed after attenuation correction, ordered subset expectation maximization (2 iterations, 28 subsets) reconstruction was used to obtain PET images. The PET/CT fusion image was

---

http://www.jcancer.org
obtained by the Siemens post processing workstation. The image was judged by two experienced physicians of nuclear medicine. All data were imported into IntelliSpace Portal v7.0 (Philips Healthcare, The Netherlands) for automatic lesion boundaries processing. SUVmax of 18F-FDG uptake in lesions were automatically calculated and assessed by two experienced nuclear medicine physicians.

**Immunohistochemical staining**

Immunohistochemical analyses were performed on paraffin-embedded RCC tissues. Sections (4mm slices) were obtained using microtome, and followingly processed for staining using a Nexes auto-immunostainer (Ventana Medical Systems, USA). Primary antibody against TIGAR was obtained from Abcam (1:400). Sections were assessed using a light microscope (BX51TR, Olympus, Japan) and a semi-quantitative IHC scoring system was applied to determine the intensity of TIGAR staining. For each section, 10 random areas were examined under the 200× magnification field of view using a Leica DFC320 digital camera system (Leica, Germany). A scale of 0 to 3 was applied to determine the intensity of IHC staining, as score of 0 represents the lack of brown staining, and score of 3 indicates intense dark brown immunoreactivity. Using this criterion, the properties of TIGAR expression was evaluated and scored by two experienced technicians who were blind to the condition of the patients. The intensity of TIGAR per section was then calculated and ranked as - (no staining), ± (weak brown staining), + (moderate brown staining), ++ (3 score, dark brown staining). The positive expression of TIGAR was defined as the moderate and strong staining (7). Where discrepancies occurred, the two technicians reached a consensus.

**Statistical analysis**

IBM SPSS Statistics Version 20.0 (SPSS Inc, USA) and GraphPad Prism 7.0 (USA) were used for data analysis. Data was presented as mean ± standard deviation (SD). The correlations between TIGAR expression and clinicopathological characteristics were evaluated using Student’s t test and Pearson’s Chi-squared (χ2) test. Receiver operating characteristic curve (ROC) analysis was calculated to determine the optimal cut-off threshold for SUVmax. The correlations between TIGAR expression and SUVmax was determined using Pearson’s correlation coefficients. Overall survival was calculated using by the Kaplan–Meier survival analysis, and comparisons were performed using the log-rank test. Univariate and multivariate regression was performed using the Cox proportional hazards model. All statistical tests were two-sided and a P value of < 0.05 was considered as statistically significant.

**Results**

**Relationship between clinical characteristics and TIGAR expression**

62 patients (42 men and 20 women) with confirmed clear cell RCC were included in this study. The average age of patients was 58.82±10.18 years old, ranged from 31 to 82 years old. The average survival time of patients was 41.14±27.26 months, ranged from 3 to 118 months. Among patients, positive TIGAR expression was found in tumor tissues of 38 patients (61.29%), while the rest 24 patients (38.71%) have negative TIGAR staining. In Table 1, we analyzed the relationship between the clinicopathological characteristics of patients and the TIGAR expression of tumor tissues. Patients were divided into negative and positive TIGAR expression groups based on the staining intensity of TIGAR. Increased TIGAR expression was associated with patients that older than 60 years old (P=0.044), with venous tumor thrombus (P=0.026), and with higher SUVmax (P=0.024). No significant correlation was found between levels of TIGAR expression and patient gender, tumor size, Fuhrman grade, lymph node metastasis or distant metastasis.

**Table 1. Baseline characteristics of patients and univariate analysis for overall survival (N=62)**

| Variables           | Subgroups          | TIGAR Expression | P value |
|---------------------|--------------------|------------------|---------|
|                     | Low (~±)           | High (+~++)      |         |
| Age                 | ≤60yrs             | 17                | 17      | 0.044   |
|                     | >60yr              | 7                | 21      |         |
| Gender              | Male               | 17                | 25      | 0.679   |
|                     | Female             | 7                | 13      |         |
| Tumor size          | ≤4cm               | 12                | 14      | 0.306   |
|                     | >4cm               | 12                | 24      |         |
| Fuhrman Grade       | Low                | 20                | 25      | 0.131   |
|                     | High               | 4                | 13      |         |
| Venous Thrombus     | No                 | 23                | 28      | 0.026   |
|                     | Yes                | 1                | 10      |         |
| Lymph Node Metastasis| No              | 20                | 29      | 0.509   |
|                     | Yes                | 4                | 9       |         |
| Distant Metastasis  | No                 | 20                | 29      | 0.509   |
|                     | Yes                | 4                | 9       |         |
| SUVmax              | 4.26±3.40          | 6.82±5.28        | 0.024   |
Positive correlation between SUVmax and TIGAR expression

In all patients, the average value of SUVmax was 5.83±4.78, ranged from 1.40 to 22.10. As stated above, the mean SUVmax of patients with positive TIGAR expression was significantly higher than those with negative TIGAR expression (P=0.024; 6.82±5.28 vs 4.26±3.40). Relationship between IHC staining intensity of TIGAR and SUVmax was then determined by Pearson’s correlation coefficient (Figure 1). A positive correlation was found between positive TIGAR expression and higher SUVmax in patients with clear cell RCC (r=0.396, 95% CI=0.1621-0.5875; P=0.001). Representative images of TIGAR staining and 18F-FDG PET/CT scans of patients with positive or negative TIGAR expression are shown in Figure 2.

Prognostic values of SUVmax and TIGAR expression in clear cell RCC

An optimal SUVmax cutoff value of 5.25 was determined by ROC analysis for predicting survival in patients with clear cell RCC (Figure 3). The area under the curve (AUC) is 0.796 (95% CI=0.659 to 0.933; P<0.001). The calculated sensitivity and specificity were 0.76 and 0.90, respectively. Using this cutoff value, Kaplan-Meier survival curves were compared between patients with SUVmax≤5.25 and those with SUVmax>5.25 (Figure 4A). Survival time was significantly shorter in patients with SUVmax>5.25 (Log-rank test, P=0.013). Comparing the Kaplan-Meier survival curves of patients with different TIGAR expression, we found that the survival time was significantly shorter in patients with positive TIGAR expression (Figure 4B; Log-rank test, P=0.013).

Univariate and multivariate analysis of the factors associated with overall survival

In the univariate Cox regression analysis, tumor size (P=0.008), Fuhrman grade (P<0.001), the presence of venous tumor thrombus (P<0.001), lymph node
metastasis ($P<0.001$), TIGAR staining intensity ($P=0.021$) and SUVmax ($P<0.001$) were associated with overall survival in patients with clear cell RCC (Table 2). While patient age, gender, the presence of distant metastasis were not significantly associated with disease survival. All factors which were significantly associated disease survival ($P<0.05$) in the univariate analysis were then entered in the multivariate Cox regression model (Table 3). The multivariate analysis revealed that Fuhrman grade ($P=0.032$) and SUVmax ($P<0.001$) were independent factors associated with overall survival in patients with clear cell RCC.

### Prognostic value of combined SUVmax and TIGAR expression

According to the SUVmax and TIGAR expression profile, all patients were divided into following three groups: patients with low SUVmax ($\leq5.25$) and negative TIGAR expression, patients with low SUVmax ($\leq5.25$) and positive TIGAR expression or with high SUVmax ($>5.25$) and negative TIGAR expression, patients with high SUVmax ($>5.25$) and positive TIGAR expression. The Kaplan-Meier survival analysis showed that the survival time was significantly shorter in patients with high SUVmax ($>5.25$) and positive TIGAR expression among three groups (Figure 5; Log-rank test $P<0.001$). No difference of survival time was observed between patients with low SUVmax and negative TIGAR expression and patients with mixed SUVmax and TIGAR profile.

### Table 2. Univariate COX regression analysis of overall survival in patients with clear cell renal cell carcinoma (N=62)

| Variables                        | Univariate analysis | HR    | 95% CI of HR | P value |
|----------------------------------|---------------------|-------|--------------|---------|
| Age                              | 1.486               | 0.627-3.517 | 0.368     |
| Gender                           | 0.846               | 0.350-2.045 | 0.711     |
| Tumor Size                       | 4.348               | 1.458-12.964 | 0.008     |
| Fuhrman Grade                    | 6.603               | 2.707-16.107 | 0.000     |
| Venous Tumor Thrombus            | 5.835               | 2.235-15.233 | 0.000     |
| Lymph Node Metastasis            | 4.887               | 2.035-11.737 | 0.000     |
| Distant Metastasis               | 2.378               | 0.956-5.919 | 0.063     |
| TIGAR Intensity                  | 3.620               | 1.214-10.795 | 0.021     |
| SUVmax                           | 5.273               | 1.914-14.527 | 0.001     |

HR: hazard ratio; CI: confidence interval.

### Table 3. Multivariate COX regression analysis of overall survival in patients with clear cell renal cell carcinoma (N=62)

| Variables                        | Multivariate analysis | HR    | 95% CI of HR | P value |
|----------------------------------|----------------------|-------|--------------|---------|
| Tumor Size                       | 0.397                | 0.043-3.638 | 0.414     |
| Fuhrman Grade                    | 0.222                | 0.056-0.881 | 0.032     |
| Venous Tumor Thrombus            | 1.410                | 0.338-5.887 | 0.637     |
| Lymph Node Metastasis            | 1.641                | 0.402-6.698 | 0.490     |
| TIGAR Intensity                  | 2.129                | 0.654-6.933 | 0.210     |
| SUVmax                           | 78.93                | 15.921-391.321 | 0.000     |

Figure 4. Kaplan-Meier overall survival curve in patients with clear cell renal cell carcinoma (RCC). (A) The survival time of patients with lower SUVmax ($\leq5.25$) is significantly higher than those with higher SUVmax ($>5.25$), $P=0.001$. (B) The survival time of patients with negative TIGAR expression is significantly higher than those with positive TIGAR expression, $P=0.013$. The + symbol represents censored subjects.

Figure 5. Kaplan-Meier overall survival curve according to SUVmax and TIGAR expression in patients with clear cell renal cell carcinoma (RCC). Higher SUVmax ($>5.25$) and positive TIGAR expression indicated a worse prognosis in patients with clear cell RCC when compared with other two groups ($P<0.001$). The + symbol represents censored subjects.
Discussion

In this study, we investigated whether the status of TIGAR expression, in addition to the SUVmax of 18F-FDG PET/CT, could provide additional prognostic information on disease survival in patients with clear cell RCC. The relationships between the tumor expression of TIGAR and the clinicopathological profiles in renal cancer are investigated in our study for the first time. As a result, increased TIGAR expression was found in about 60% of patients with clear cell RCC. The levels of TIGAR expression was positively correlated with tumor SUVmax of FDG uptake. Specifically, positive TIGAR expression and high SUVmax (>5.25) are associated with a poor disease prognosis in these patients, and SUVmax is recognized as an independent predictive factors for disease survival. A worse disease survival is suggested in clear cell RCC patients with positive TIGAR expression and high SUVmax.

TIGAR has been identified as a p53 target protein that serves a tumor suppressing role via regulating glycolytic activity and redox hemostasis. It shares a similar structure as phosphofructokinase 2/fructose-2,6-bisphosphatase (PFK-2/FBPase-2) and lowers glycolytic flow via degrading fructose-2,6-bisphosphate (F-2,6-P2) and inhibits phosphofructokinase 1 (PFK-1) activity [19]. Considering the hallmark of reprogrammed metabolic pathways in cancer cells, it is not surprising to find dysregulated TIGAR expression in various cancer types, including lung cancer, intestinal cancer, liver cancer, and glioma [22, 25-27]. Significantly elevated TIGAR expression was shown to promote tumorigenesis in primary colon cancer and metastatic sites [27]. Compared to normal tissues, invasive breast cancer was associated with an higher expression of TIGAR [28]. Similarly, increased TIGAR expression was found in glioblastoma [25]. In our study, positive TIGAR expression was found in 61.29% (38/62) of clear cell RCC patients. The increased TIGAR protein level was associated with older age, venous tumor thrombus, and higher SUVmax in our cohort. More importantly, a shorter survival time was found in clear cell RCC patients with positive TIGAR compared with those with negative TIGAR expression (HR=3.620, 95% CI 1.089-1.614). As a result, increased TIGAR expression and increased SUVmax in patients with clear cell RCC. It has been suggested overexpressed TIGAR may exert a tumor promoting function uncoupled from p53 expression [27]. TIGAR is known to bind with and active the rate-limiting glucose metabolic enzyme hexokinase 2 (HK2), and in turn increases the production of metabolic intermediates and promotes cell proliferation via PPP [29, 30].

In normal cells, the expression of TIGAR level is tightly regulated during different stages of p53 induced cell death. The TIGAR level first upregulated during the initial stage of p53 induced cell stress, and then drops when the cells are under a transition towards an apoptotic state [19]. Interestingly, contrary to its function in the p53 tumor suppression pathway, our study revealed a significant correlation between increased TIGAR expression and increased SUVmax in patients with clear cell RCC. It has been suggested overexpressed TIGAR may exert a tumor promoting function uncoupled from p53 expression [27]. TIGAR is known to bind with and active the rate-limiting glucose metabolic enzyme hexokinase 2 (HK2), and in turn increases the production of metabolic intermediates and promotes cell proliferation via PPP [29, 30]. Given the well documented Warburg effect, most tumor cells exerts an upregulated aerobic glycolysis and glucose metabolism under adequate oxygen supply. Elevated SUVmax of 18F-FDG suggested an enhanced glycolytic activity and glucose metabolism in tumor cells, which is associated with the upregulation of glycolytic enzymes including HK2 [31]. According to the upregulated TIGAR expression along with the high SUVmax in our results, it is possible that an upregulated glycolytic and PPP activity may occur in these patients with
clear cell RCC. Consistent with our findings, a recent in vivo isotope tracing study revealed a significantly increased enrichment of glycolytic intermediates and a lowest TCA cycle intermediate enrichment, suggesting enhanced glycolysis and suppressed mitochondrial oxidation in clear cell RCC [32]. It is worthy to notice that correlation between TIGAR expression and SUVmax can vary depending on different cancer types, and may serve as a potential indicator for glucose metabolic phenotypes. Unlike clear cell RCC with an enhanced glycolysis and inhibited phosphorylation oxidation, studies revealed a preserved mitochondrial oxidation function in human lung cancers [33, 34]. Consistently, our previous study also revealed an opposite relationship between TIGAR expression and SUVmax in patients with lung cancers, as negative TIGAR expression was significantly associated with higher SUVmax [22]. Based on our findings and previous publications, the combined use of SUVmax and TIGAR may provide additional information regarding the changes of glucose metabolic flux in different types of tumors.

The present study has a few limitations. Firstly, the retrospective study design may subject to the selection bias. Secondly, a relatively small number of patients was included in this study, which also may contribute to selection bias. Thirdly, due to the limited sample size, it is difficult for us to have a separate patient cohort to validate the major findings. We currently are planning to conduct a prospective clinical study in collaboration with urology surgeons to collect more renal cancer cases to better address and validate the prognostic value the TIGAR expression and SUVmax in renal cancer.

In conclusion, our study is so far the first report evaluated the prognostic value of TIGAR expression and SUVmax in patients with clear cell RCC. SUVmax and Fuhrman grade are found to be independent predictors for prognosis. A positive TIGAR expression was correlated with increased SUVmax. Patients who have positive TIGAR expression and high SUVmax were associated with a worse disease overall survival. Combined use of TIGAR expression and 18F-FDG PET/CT may provide additional information to help evaluate glucose metabolism and disease prognosis in clear cell RCC.

Abbreviations

18F-FDG PET/CT: 18F-fluorodeoxyglucose positron emission tomography/computerized tomography; F-2,6-P2: fructose-2,6-bisphosphate; HK2: hexokinase 2; IHC: Immunohistochemistry; FBPase-2: fructose-1,6-bisphosphatase; PFK-1: phosphofructokinase 1; PFK-2: phosphofructokinase 2; PPP: pentose phosphate pathway; ROC: receiver operating characteristic curve; RCC: renal cell carcinoma; SUVmax: maximal standardized uptake value; TIGAR: p53-induced glycolysis and apoptosis regulator.

Acknowledgement

This work is supported by grants from the National Natural Science Foundation of China (No. 81571710, 30830038, 30970842, 81071180 and 81601520).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Motzer RJ, Agarwal N, Bead C, et al. Kidney cancer. J Natl Compr Canc Netw. 2011; 9: 960-77.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
3. Low G, Huang G, Fu W, et al. Review of renal cell carcinoma and its common subtypes in radiology. World Journal of Radiology. 2016; 8: 484-500.
4. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002; 4: 163-70.
5. Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 2011; 104: 399-408.
6. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005; 23: 2763-71.
7. Moch H, Canner T, Amin MB, et al. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000; 89: 604-14.
8. Oliva MR, Glickman JN, Zou KH, et al. Renal cell carcinoma: T1 and T2 signal intensity characteristics of papillary and clear cell types correlated with pathology. AJR Am J Roentgenol. 2009; 192: 1524-30.
9. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002; 168: 2395-400.
10. Caruso R, Farisi A, Bonanno A, et al. Histologic coagulative tumor necrosis as a prognostic indicator of aggressiveness in renal, lung, and colorectal carcinomas: A brief review. Oncol Lett. 2012; 3: 16-8.
11. Margulis V, Tamholi P, Martin SF, et al. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer. 2008; 112: 1480-8.
12. Pinilla I, Rodriguez-Vigil B, Gomez-Leon N. Integrated FDG PET/CT: Utility and Applications in Clinical Oncology. Clin Med Oncol. 2008; 2: 181-98.
13. Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/CT imaging in oncology. Ann Saudi Med. 2011; 31: 3-13.
14. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends in biochemical sciences. 2016; 41: 211-8.
15. Lee HJ, Lee JJ, Park JY, et al. Prognostic value of metabolic parameters determined by preoperative (18F)-FDG-PET/CT in patients with uterine carcinosarcoma. Journal of Gynecologic Oncology. 2017; 28: e43.
16. Namura K, Minamimoto R, Yao M, et al. Impact of maximum standardized uptake value (SUVmax) evaluated by 18F-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010; 10: 567.
17. Ferda J, Ferruda E, Hora M, et al. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Anticancer Res. 2013; 33: 2665-72.
18. Li H, Joogl G. Structural and biochemical studies of TIGAR (TIPS3-induced glycolysis and apoptosis regulator). J Biol Chem. 2009; 284: 17484-54.
19. Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. J Biol Chem. 2009; 284: 17484-54.
20. Hong M, Xia Y, Zhu Y, et al. TIPS3-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia. Leukemia Research. 2016; 50: 72-7.
21. Qian S, Li J, Hong M, et al. TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia. Journal of Hematology & Oncology. 2016; 9: 128.
Zhou X, Xie W, Li Q, et al. TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer. PLoS One. 2013; 8: e80576.

Zigeuner R, Ratschek M, Rehak P, et al. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology. 2004; 63: 651-5.

Corcoran CA, Huang Y, Sheikh MS. The regulation of energy generating metabolic pathways by p53. Cancer Biol Ther. 2006; 5: 1610-3.

Wanka C, Steinbach JP, Rieger J. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem. 2012; 287: 33436-46.

Zou S, Gu Z, Ni P, et al. SPI plays a pivotal role for basal activity of TIGAR promoter in liver cancer cell lines. Mol Cell Biochem. 2012; 359: 17-23.

Cheung EC, Athineos D, Lee P, et al. TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell. 2013; 25: 463-77.

Ko YH, Domingo-Vidal M, Roche M, et al. TP53-inducible Glycolysis and Apoptosis Regulator (TIGAR) Metabolically Reprograms Carcinoma and Stromal Cells in Breast Cancer. J Biol Chem. 2016; 291: 26291-303.

Cheung EC, Ludvig RL, Vousden KH. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci U S A. 2012; 109: 20491-6.

Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013; 24: 213-28.

Baschnagel AM, Wobb JL, Dilworth JT, et al. The association of (18)F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas. Radiother Oncol. 2015; 117: 118-24.

Courtney KD, Bezwada D, Mashimo T, et al. Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. Cell Metab. 2018; 28: 793-800 e2.

Hensley CT, Faubert B, Yuan Q, et al. Metabolic Heterogeneity in Human Lung Tumors. Cell. 2016; 164: 681-94.

Sellers K, Fox MP, Bousamra M, et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J Clin Invest. 2015; 125: 687-98.